These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1321457)

  • 1. Effects of treatments by calcium and sex hormones on vertebral fracturing in osteoporosis.
    Almustafa M; Doyle FH; Gutteridge DH; Hand DJ; Davis TM; Spinks TJ; Freemantle C; Joplin GF
    Q J Med; 1992 Apr; 83(300):283-94. PubMed ID: 1321457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.
    Riggs BL; Seeman E; Hodgson SF; Taves DR; O'Fallon WM
    N Engl J Med; 1982 Feb; 306(8):446-50. PubMed ID: 6276746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD; Kipshoven C; Cöster A; Umbach R
    Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K; Fukunaga M; Kishimoto H; Shiraki M; Itabashi A; Inoue T; Kaneda K; Morii H; Nawata H; Yamamoto K; Ohashi Y; Orimo H
    J Bone Miner Metab; 2004; 22(5):469-78. PubMed ID: 15316868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of postmenopausal osteoporosis with calcitriol or calcium.
    Tilyard MW; Spears GF; Thomson J; Dovey S
    N Engl J Med; 1992 Feb; 326(6):357-62. PubMed ID: 1729617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
    J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being.
    Flöter A; Nathorst-Böös J; Carlström K; von Schoultz B
    Climacteric; 2002 Dec; 5(4):357-65. PubMed ID: 12626215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
    Heaney RP; Zizic TM; Fogelman I; Olszynski WP; Geusens P; Kasibhatla C; Alsayed N; Isaia G; Davie MW; Chesnut CH
    Osteoporos Int; 2002; 13(6):501-5. PubMed ID: 12107665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly--a 12- and 22-year follow-up of 257 patients.
    Hasserius R; Karlsson MK; Jónsson B; Redlund-Johnell I; Johnell O
    Calcif Tissue Int; 2005 Apr; 76(4):235-42. PubMed ID: 15812579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex steroids and bone turnover markers in men with symptomatic vertebral fractures.
    Tuck SP; Scane AC; Fraser WD; Diver MJ; Eastell R; Francis RM
    Bone; 2008 Dec; 43(6):999-1005. PubMed ID: 18817902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
    Ringe JD; Dorst A; Kipshoven C; Rovati LC; Setnikar I
    Osteoporos Int; 1998; 8(1):47-52. PubMed ID: 9692077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium metabolism in postmenopausal osteoporosis: the influence of dietary calcium and net absorbed calcium.
    Hasling C; Charles P; Jensen FT; Mosekilde L
    J Bone Miner Res; 1990 Sep; 5(9):939-46. PubMed ID: 2281824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome.
    Rico H; Hernandez ER; Revilla M; Gómez-Castresana F
    Bone Miner; 1992 Feb; 16(2):131-8. PubMed ID: 1576488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.